Page last updated: 2024-11-06

acetaminophen cysteine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

acetaminophen cysteine: an acetaminophen metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID83997
CHEBI ID177963
MeSH IDM0190242

Synonyms (14)

Synonym
CHEBI:177963
64014-06-8
(2r)-3-(4-acetamidophenyl)sulanyl-2-aminopropanoic acid
acetaminophen cystein
aa-cysteine
acetaminophen cysteine
l-cysteine, s-(4-(acetylamino)phenyl)-
s-(4-(acetylamino)phenyl)-l-cysteine
(2r)-3-(4-acetamidophenyl)sulfanyl-2-aminopropanoic acid
acetaminophen-cysteine
DTXSID60214000
AKOS028112517
l-cysteine, s-[4-(acetylamino)phenyl]-
PS-12008

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Indeed, pretreatment of male CD-1 mice with APAP-CYS before challenge with a threshold toxic dose of APAP resulted in significant enhancement of APAP-induced nephrotoxicity."( Contribution of acetaminophen-cysteine to acetaminophen nephrotoxicity in CD-1 mice: I. Enhancement of acetaminophen nephrotoxicity by acetaminophen-cysteine.
Bruno, MK; Cohen, SD; Hennig, GE; Horton, RA; Roberts, JC; Stern, ST, 2005
)
0.33
" This APAP-CYS-induced renal GSH depletion could interfere with intrarenal detoxification of APAP or its toxic metabolite N-acetyl-p-benzoquinoneimine (NAPQI) and may be the mechanism responsible for the potentiation of APAP nephrotoxicity."( Contribution of acetaminophen-cysteine to acetaminophen nephrotoxicity II. Possible involvement of the gamma-glutamyl cycle.
Bruno, MK; Cohen, SD; Hill, DW; Horton, RA; Roberts, JC; Stern, ST, 2005
)
0.33

Pharmacokinetics

ExcerptReferenceRelevance
" However, a significantly shorter elimination half-life of PCM was observed in the thalassemic subjects (p<0."( A pharmacokinetic study of paracetamol in Thai beta-thalassemia/HbE patients.
Chantharaksri, U; Fucharoen, P; Fucharoen, S; Howard, TA; Morales, NP; Sanvarinda, Y; Sirankapracha, P; Tankanitlert, J; Temsakulphong, A; Ware, RE, 2006
)
0.33
" Our pharmacokinetic data provide additional evidence that plasma PCM-G is higher in thalassemic patients with hyperbilirubinemia, which could be a casual relationship in regulating the UDP-glucuronosyltransferase expression."( A pharmacokinetic study of paracetamol in Thai beta-thalassemia/HbE patients.
Chantharaksri, U; Fucharoen, P; Fucharoen, S; Howard, TA; Morales, NP; Sanvarinda, Y; Sirankapracha, P; Tankanitlert, J; Temsakulphong, A; Ware, RE, 2006
)
0.33
"The pharmacokinetic (PK) profile of a drug is influenced by several factors, which can lead to a suboptimal dosing regimen in specific patient populations."( Application of a Volumetric Absorptive Microsampling (VAMS)-Based Method for the Determination of Paracetamol and Four of its Metabolites as a Tool for Pharmacokinetic Studies in Obese and Non-Obese Patients.
Boffel, L; De Baerdemaeker, L; Delahaye, L; Stove, CP, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" It is not clear why regular dosing with paracetamol in haemodialysis patients did not cause the accumulation of paracetamol glucuronide or sulphate as predicted."( The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis.
Martin, U; Prescott, LF; Temple, RM; Winney, RJ, 1993
)
0.29
"5, 2, 3, 4, 5, 7, and 9 h after dosing for determination of the plasma levels of PCM and its metabolites by high-performance liquid chromatography."( A pharmacokinetic study of paracetamol in Thai beta-thalassemia/HbE patients.
Chantharaksri, U; Fucharoen, P; Fucharoen, S; Howard, TA; Morales, NP; Sanvarinda, Y; Sirankapracha, P; Tankanitlert, J; Temsakulphong, A; Ware, RE, 2006
)
0.33
" However, the concentrations of APAP-CYS during therapeutic dosing, in cases of acetaminophen toxicity from repeated dosing and in cases of hepatic injury from non-acetaminophen hepatotoxins have not been well characterized."( Acetaminophen-cysteine adducts during therapeutic dosing and following overdose.
Dart, RC; Green, JL; Heard, KJ; James, LP; Judge, BS; Rhyee, S; Zolot, L, 2011
)
0.37
" Trial 1 consisted of non-drinkers who received APAP for 10 days, Trial 2 consisted of moderate drinkers dosed for 10 days and Trial 3 included subjects who chronically abuse alcohol dosed for 5 days."( Acetaminophen-cysteine adducts during therapeutic dosing and following overdose.
Dart, RC; Green, JL; Heard, KJ; James, LP; Judge, BS; Rhyee, S; Zolot, L, 2011
)
0.37
" Adducts are detectable after a few doses and can persist for over a week after dosing is stopped."( Paracetamol (acetaminophen) protein adduct concentrations during therapeutic dosing.
Anderson, V; Bucher-Bartelson, B; Dart, RC; Green, JL; Heard, K, 2016
)
0.43
"The pharmacokinetic (PK) profile of a drug is influenced by several factors, which can lead to a suboptimal dosing regimen in specific patient populations."( Application of a Volumetric Absorptive Microsampling (VAMS)-Based Method for the Determination of Paracetamol and Four of its Metabolites as a Tool for Pharmacokinetic Studies in Obese and Non-Obese Patients.
Boffel, L; De Baerdemaeker, L; Delahaye, L; Stove, CP, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
S-conjugateA bioconjugate containing molecules covalently bonded by a sulphur linkage
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Acetaminophen Metabolism Pathway3016

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (13.04)18.2507
2000's8 (34.78)29.6817
2010's10 (43.48)24.3611
2020's2 (8.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.38 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index40.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (13.04%)5.53%
Reviews1 (4.35%)6.00%
Case Studies1 (4.35%)4.05%
Observational1 (4.35%)0.25%
Other17 (73.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]